Gesine Benze|Friedemann Nauck|Bernd Alt?Epping|Giuseppe Gianni|Thomas Bauknecht|Johannes Ettl|Anna Munte|Luisa Kretzschmar|Jan Gaertner
PROutine: a feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer
Universitätsmedizin Göttingen|Universitätsmedizin Göttingen|Universitätsmedizin Göttingen|AppPeople (Germany)|AppPeople (Germany)|Rechts der Isar Hospital|Rechts der Isar Hospital|Charité - Universitätsmedizin Berlin
background advanced cancer quality life qol major treatment goal order achieve identification suffering screening patientreportedoutcomes pros ie symptoms utmost importance use paperpencil questionnaires associated significant shortcomings due missing data recall bias transcription errors electronic recording pros mobile health mhealth offers number advantages aim study test whether routine assessment pros via newly developed smartphone application meqol feasible methods prospective uncontrolled multicenter feasibility trial performed adult outpatients advanced solid cancer patients anticancer therapy regular outpatient visits eligible patients daily recorded degree perceived distress nccn distress thermometer pain intensity average worst numerical rating scale nrs 010 number breakthrough pain episodes bpe ten questions modified version edmonton symptom assessment scale esas weekly five questions concerning different domains qol shortform 8 sf8 questionnaire obtained also patients recorded intake opioid rescue medication according main scope trial feasibility primary endpoint defined rather following main feasibility criteria assessed missing data dropout acceptancerate patient satisfaction patients judgement practicability patients physicians suggestions improvement basic clinical demographic data participating patients study registered german clinical trials register id drks00008761 results three german cancer centers 40 patients female 28 70 average age 57 years range 2773 years standard deviation sd 12 included three devices lost transport 37 devices could evaluated median investigation period per device 995 days sd 31 patient adherence using smartphone app document distress symptoms high missing data low median daily reviews performed 70 sd 29 days 70 median weekly recordings 13 weeks 87 often patients recorded symptom intensity 89 midos distress 85 nccn thermometer feedback forms patients reported good good user friendliness meqol high motivation use tool conclusions even though participants asked record pros rather frequently daily missing data low patient satisfaction high mind findings working groups routine implementation mhealth solutions may substantially improve outcomes cancer therapy increase value trials findings individual patient meqol allows monitoring adherence pharmacotherapy facilitate patient guidance